A potential criticism of our line of thinking could be that there is no haploinsufficient effect of a BRCA1 or BRCA2 mutation, and that anti-oestrogen treatment functions only as a secondary preventer of breast cancer. Here, BRCA2 is linked to breast carcinoma.